• MS & Me
  • MS Info Hub
  • MS News
  • MS Radio

Novartis multiple sclerosis drug Gilenya shows siginificant effect against pediatric MS in phase III...

Novartis MS Drug Gilenya shows siginificant effect in phase III trial: Against Pediatric MSNovartis’ multiple sclerosis (MS) drug Gilenya (fingolimod) has demonstrated significant effect...

Multiple Sclerosis: Are we close to a cure?

Hannah Nichols recently posed this question in Medical News Today, "Researchers are uncovering many potential treatment routes for MS. Could they be close to...

Could Probiotics Help to Fight Multiple Sclerosis?

Breaking research from the Mayo Clinic uncovers a gut microbe that has the potential to treat autoimmune diseases, including multiple sclerosis. The intriguing findings...
video

University of Calgary research using acne medication to combat MS

A Canadian clinical trial led by researchers at the University of Calgary's Hotchkiss Brain Institute (HBI), at the Cumming School of Medicine (CSM), shows...
video

Cladridbine for the Treatment of Multiple Sclerosis

Dr. Daniel Kantor speaks with Dr. Kottil Rammohan, Professor of Neurology at University of Miami and Director of the MS Center about Cladribine for...

Mallinckrodt Acthar Gel phase IV clinical study with relapsing multiple sclerosis

STAINES-UPON-THAMES, United Kingdom Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4...

A U.S. Food and Drug Administration (FDA) review to date has not identified adverse...

A U.S. Food and Drug Administration (FDA) review to date has not identified adverse health effects from gadolinium retained in the brain after the...

Roche seeks partners for remyelination therapies

Roche Holding AG is seeking a partner with experimental drugs that might help repair the damage caused to the nervous system by multiple sclerosis...

Celgene announces data on its phase III relapsing MS Ozanimod experimental treatment

Study met the primary endpoint of annualized relapse rate (ARR) and key secondary MRI endpoints of T2 and GdE lesions, compared to interferon (IFN)...

Social Media

531FollowersFollow